Prof. Ronald B. Moss

Adamis Pharmaceuticals, USA
Chief Medical Officer

Email: [email protected]

Qualifications

1982-1988 M.D., The Chicago Medical School, Medicine

1978-1982 B.A., State University of New York, Psychology/Bioethics

Publications (selected)

1. Moss, R., Del Rosario, J., Vishwanath, S., et al. (2025). Development of Pan-H5 Vaccines Against Avian Influenza Developed Using Computational Biology to Mitigate Future Pandemics. Journal of Allergy and Clinical Immunology, 155(2, Suppl. S), AB448.
2. Mathi, K., Rosenberg-Hasson, Y., Maecker, H., et al. (2021). Brief report: Tempol, a novel antioxidant, inhibits both activated T cell and antigen presenting cell derived cytokines in-vitro from COVID-19 patients. Clinical Immunology, 231, Article 108828.
3. Moss, R. B., Pryor, M. M., Baillie, R., et al. (2020). Higher naloxone dosing in a quantitative systems pharmacology model that predicts naloxone-fentanyl competition at the opioid mu receptor level (vol 15, e0234683, 2020). PLOS ONE, 15(9), Article e0240148.
4. Moss, R. B., Pryor, M. M., Baillie, R., et al. (2020). Higher naloxone dosing in a quantitative systems pharmacology model that predicts naloxone-fentanyl competition at the opioid mu receptor level. PLOS ONE, 15(6), Article e0234683.
5. Scott, P. J. H., Koeppe, R. A., Shao, X., et al. (2020). The Effects of Intramuscular Naloxone Dose on Mu Receptor Displacement of Carfentanil in Rhesus Monkeys. Molecules, 25(6), Article 1360.
6. Moss, R. B., Moll, T., Daniels, K., et al. (2018). Human factors study of a newly approved prefilled syringe of epinephrine for the treatment of anaphylaxis. Allergy and Asthma Proceedings, 39(5), 389-393.
7. Moss, R. B., Daniels, K., Moll, T., et al. (2018). Human factors study in untrained adolescents comparing a recently approved single-dose epinephrine prefilled syringe with an approved autoinjector. Annals of Allergy Asthma & Immunology, 120(5), 540-541.
8. Moss, R. B., Moll, T., Daniels, K., et al. (2018). Human Factors Study of a Newly Approved Epinephrine Prefilled syringe (PFS) for the Emergency Treatment of Allergic Reactions (Type I) including Anaphylaxis. Journal of Allergy and Clinical Immunology, 141(2, Suppl. S), AB39.
9. Moss, R. B. (2018). Anaphylaxis: getting to the point (and price) of diagnosis and treatment. Journal of Asthma and Allergy, 11, 109-110.
10. Moss, R. B. (2016). Enterovirus 68 Infection-Association with Asthma. Journal of Allergy and Clinical Immunology-In Practice, 4(2), 226-228.
11. Silveira, F. P., Abdel-Massih, R., Bogdanovich, T., et al. (2016). Treatment of resistant influenza virus infection in a hospitalized patient with cystic fibrosis with DAS181, a host-directed antiviral. Antiviral Therapy, 21(1), 71-74.
12. Cushing, A., Kamali, A., Winters, M., et al. (2015). Emergence of Hemagglutinin Mutations During the Course of Influenza Infection. Scientific Reports, 5, Article 16178.
13. Waghmare, A., Wagner, T., Andrews, R., et al. (2015). Successful Treatment of Parainfluenza Virus Respiratory Tract Infection With DAS181 in 4 Immunocompromised Children. Journal of the Pediatric Infectious Diseases Society, 4(2), 114-118.
14. Chalkias, S., Mackenzie, M. R., Gay, C., et al. (2014). DAS181 treatment of hematopoietic stem cell transplant patients with parainfluenza virus lung disease requiring mechanical ventilation. Transplant Infectious Disease, 16(1), 141-144.
15. Nicholls, J. M., Moss, R. B., & Haslam, S. M. (2013). The use of sialidase therapy for respiratory viral infections. Antiviral Research, 98(3), 401-409.
16. Drozd, D. R., Limaye, A. P., Moss, R. B., et al. (2013). DAS181 treatment of severe parainfluenza type 3 pneumonia in a lung transplant recipient. Transplant Infectious Disease, 15(1), E28-E32.
17. Moss, R. B., Hansen, C., Sanders, R. L., et al. (2012). A Phase II Study of DAS181, a Novel Host Directed Antiviral for the Treatment of Influenza Infection. Journal of Infectious Diseases, 206(12), 1844-1851.
18. Guzmán-Suarez, B. B., Buckley, M. W., Gilmore, E. T., et al. (2012). Clinical potential of DAS181 for treatment of parainfluenza-3 infections in transplant recipients. Transplant Infectious Disease, 14(4), 427-433.

Profile Details

https://www.researchgate.net/profile/Ron-Moss-2

WOS ResearcherID: FMX-1762-2022